

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/076006 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) *A61P 21/00* (2006.01)
A61K 31/712 (2006.01) *C07K 14/47* (2006.01)
A61K 31/7125 (2006.01) *C07K 16/28* (2006.01)
A61K 47/68 (2017.01) *A61K 31/7088* (2006.01)

(21) International Application Number:

PCT/US2024/049484

(22) International Filing Date:

01 October 2024 (01.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/587,394 02 October 2023 (02.10.2023) US

(71) Applicant: **AVIDITY BIOSCIENCES, INC.** [US/US];
10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

(72) Inventors: **DARIMONT, Beatrice Diana**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **ETXANIZ IRIGOIEN, Usue**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **DOPPALAPUDI, Venkata Ramana**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **COCHRAN, Michael Caramian**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

ter Drive, Suite 125, San Diego, California 92121 (US). **MARKS, Isaac**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **ALBIN, Tyler**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

(74) Agent: **SHIN, Minyoung** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING




FIG. 3

(57) Abstract: Disclosed herein are binding moiety (e.g., antibody)- oligonucleotide (e.g., PMO) conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce DMD exon 45 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering such conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce DMD exon 45 skipping.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

15 May 2025 (15.05.2025)